Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03626714

Enrollment

Registered

2018-08-13

Start date

2018-10-16

Completion date

2019-01-05

Last updated

2019-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organ Transplant Rejection, Psoriasis

Keywords

Tacrolimus, Immunosuppressant, Sustained-release, Plexis

Brief summary

This first-in-human study is designed to assess the safety and pharmacokinetic (PK) profile of sustained-release (SR) depot tacrolimus, which will be administered as a single dose of 0.1 mg/kg by subcutaneous (SC) injection in healthy subjects.

Detailed description

This is a first-in-human study to assess the safety and pharmacokinetic (PK) profile of sustained-release (SR) tacrolimus, which will be administered as a single dose of 0.1 mg/kg by subcutaneous (SC) injection in healthy subjects. The short-term general investigational plan is to evaluate sustained release tacrolimus in healthy volunteers for up to 30 days in an exploratory trial to determine safety and drug concentrations in blood. The results from this study will inform the long-term goal of this program, which is to provide an improved treatment modality for prophylaxis of organ (kidney, liver and heart) transplant rejection with the additional benefit of enhancing medication compliance. These improvements have the potential to mitigate both the personal and economic burden of this disease.

Interventions

DRUGSustained Release Injectable Tacrolimus

Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments are done; * Males or females, between 18 and 45 years of age, inclusive; * Body mass index must be within the range 18.5 to 32.0 kg/m2, inclusive; * Must be in good health, as determined by no clinically significant findings from medical history, vital signs, and 12-lead electrocardiogram (ECG), inclusive of documented absence of QT prolongation; * Clinical laboratory evaluations (including clinical chemistry panel \[fasted at least 10 hours\], complete blood count \[CBC\], and urinalysis \[UA\]) must be within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator; * Must be negative for autoimmune disorders in the past 3 months and at Screening - participant's medical history will be used for this evaluation; * Must not use any immunosuppressant calcineurin inhibitor product other than SR Injectable tacrolimus throughout the dosing period and until after the final visit; * Must agree to blood draws throughout the course of the study and venous access sufficient to allow for blood sampling as per the protocol; * Must be negative for selected drugs of abuse at Screening and at Check-in (Day -1); * Must have a negative hepatitis panel (including hepatitis B surface antigen \[HBsAg\] and hepatitis C virus antibody \[HCV\]) and negative human immunodeficiency virus \[HIV\] antibody screens; * Females will be nonpregnant, nonlactating, and either postmenopausal, defined as amenorrhea for at least 1 year and follicle-stimulating hormone levels of 40 mIU/mL or higher; surgically sterile (eg, tubal ligation, hysterectomy, oophorectomy) for at least 90 days prior to Screening; or agree to use, from the time of signing the informed consent or 10 days prior to Check-in on Day -1 of the Inpatient Period until 30 days after Study Discharge, one of the following forms of contraception: nonhormonal intrauterine device (IUD) with spermicide; female condom with spermicide; contraceptive sponge with spermicide; diaphragm with spermicide; cervical cap with spermicide; male sexual partner who agrees to use a male condom with spermicide; or sterile sexual partner; alternatively, women must agree to maintain abstinence (must agree to use a double barrier method if they become sexually active during the study. For all females of childbearing potential, the pregnancy test result must be negative at Screening and Check-in on Day -1 of the Inpatient Period (see Appendix 1). Women must also agree not to douche throughout the dosing period and until after the final visit; * Males will either be sterile or agree to use, from Check-in on Day -1 of the Inpatient Period until 90 days following Study Discharge, one of the following approved methods of contraception: male condom with spermicide; sterile sexual partner; or use by female sexual partner of an IUD with spermicide; a female condom with spermicide; a contraceptive sponge with spermicide; an intravaginal system (eg, NuvaRing®); a diaphragm with spermicide; a cervical cap with spermicide; or oral, implantable, transdermal, or injectable contraceptives. Subjects will refrain from sperm donation from Check-in on Day -1 of the Inpatient Period until 90 days following Study Discharge.

Exclusion criteria

* Inability or unwillingness of a participant to give written informed consent or comply with study protocol; * Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness must not be enrolled into this trial; * Presence of an uncontrolled, unstable clinically significant medical condition that in the opinion of the Investigator may increase the risk to the subject or may interfere with the interpretation of safety and PK evaluations, or could impair the subject's ability to complete the trial, or could impair the decisional capacity of the subject; * Presence of clinically significant vital signs or a physical examination finding that, in the opinion of the Investigator, could increase the risk to the subject or may potentially interfere with the ability to evaluate safety and tolerability in the trial; * History of tacrolimus use, or hypersensitivity and/or adverse reaction to calcineurin inhibitor drugs; * History of toxic shock syndrome; * Currently receiving chemotherapy or immunosuppressive agents; * Use of investigative drugs within 30 days or 5 half-lives of study participation; * Currently using sirolimus; * Currently using live vaccines; * Currently on concomitant substrates and/or inhibitors of CYP3A4; * Requires the use of any concomitant medication, except for treatment of an adverse event (AE) during the study; * Any abnormality on clinical laboratory tests, or ECG finding that is considered to be clinically significant by the Investigator. * Known or suspected (nonfebrile) seizure disorder; * Use of any other depot medications within the last three months. * Unwilling to commit to avoid eating grapefruit or drinking grapefruit juice during the first 30 days of this exploratory study. * Grade ≥ 1 finding as described in the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials

Design outcomes

Primary

Measure	Time frame	Description
Mean Blood Concentration-time Curve - Cmax	60 days	Maximum observed tacrolimus whole blood concentration
Number of Subjects That Experienced Treatment-related Adverse Events [Safety and Tolerability]	60 days	Adverse events were documented at each study visit according to the criteria set forth in the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials as follows: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (potentially life-threatening).
Drug Concentrations in Blood Samples at Individual Time-points	60 days	The concentrations of tacrolimus in blood samples were measured at baseline, day 1 (1 hr, 3 hrs, 6 hrs, 12 hrs, and 24 hrs), followed by days 3, 7, 14, 21, 30, 37, 44, 51 and 60.
Mean Blood Concentration-time Curve - Tmax	60 days	Time to maximum observed tacrolimus whole blood concentration
Blood Concentration-time Curve [AUC]	60 days	Area under the concentration-time curve
Terminal Elimination Half-life [t1/2]	60 days	The apparent terminal elimination half-life was calculated.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Experimental: Sustained Release Injectable Tacrolimus All subjects will be treated with a single dose injection of sustained-release Tacrolimus.	8
Total	8

Baseline characteristics

Characteristic	Experimental: Sustained Release Injectable Tacrolimus
Age, Continuous	34.37 years
Ethnicity (NIH/OMB) Hispanic or Latino	6 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	2 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants
Race (NIH/OMB) Asian	0 Participants
Race (NIH/OMB) Black or African American	3 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	5 Participants
Region of Enrollment United States	8 participants
Sex: Female, Male Female	4 Participants
Sex: Female, Male Male	4 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 8
other Total, other adverse events	8 / 8
serious Total, serious adverse events	0 / 8

Arm	Measure	Value (MEAN)	Dispersion
Experimental: Sustained Release Injectable Tacrolimus	Terminal Elimination Half-life [t1/2]	1100 hours	Standard Deviation 803

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Countries

Participant flow

Participants by arm

Baseline characteristics

Adverse events

Outcome results

Blood Concentration-time Curve [AUC]

Drug Concentrations in Blood Samples at Individual Time-points

Mean Blood Concentration-time Curve - Cmax

Mean Blood Concentration-time Curve - Tmax

Number of Subjects That Experienced Treatment-related Adverse Events [Safety and Tolerability]

Terminal Elimination Half-life [t1/2]